Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes.
Rigshospitalet, Copenhagen, Denmark.
Mikkel M
MM
Schoos
Rigshospitalet, Copenhagen, Denmark.
Peter
P
Clemmensen
Mount Sinai Medical Center, New York, New York. Electronic address: gdangas@crf.org.
George D
GD
Dangas
D020341:Absorbable Implants; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000628:therapy*; D023921:Coronary Stenosis / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000209:etiology* / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
D002317:Cardiovascular Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus
bioresorbable scaffold; coronary artery disease; diabetes mellitus; drug-eluting stent